

Carbapenem-resistant *Enterobacteriaceae* Surveillance Report

January - March, 2020

Carbapenem-resistant *Enterobacteriaceae* (CRE) are a family of bacteria with high levels of resistance to antibiotics. Data from reported, confirmed CRE cases, to the Philadelphia Department of Public Health, occurring in January-March 2020 (n=64) are displayed. 35 of the cases were lab-confirmed to be carbapenemase-producing CRE (CP-CRE), 10 were non-CP CRE and 19 were not tested. Available CP mechanisms are shown in the table below. Not all isolates were sent for mechanism testing. This is the first report that excludes the species in the Morganellaceae family such as *Morganella morganii*, *Providencia spp.* and *Proteus Spp.*, which were previously classified as *Enterobacteriaceae* but are now considered a separate family and therefore will no longer be included in the CRE report.

Carbapenemase-Producing (CP) Status of Confirmed Cases	
CP-CRE	35 (55%)
Non-CP CRE	10 (16%)
CP Status Pending/ Not Tested	19 (30%)
Total Confirmed CRE Cases	64

CRE Counts ¹ , by Genus Species and Mechanism (n=64)							
Genus Species	Total CRE n (%)	Total CP-CRE	KPC	NDM	OXA-48	IMP	VIM
<i>Klebsiella pneumoniae</i>	31 (48.4)	21	19	2	.	.	.
<i>Escherichia coli</i>	10 (15.6)	6	2	4	.	.	.
<i>Enterobacter cloacae</i>	6 (9.4)	4	4
Other <i>Klebsiella Spp</i>	4 (6.3)	1	1
Other <i>Enterobacteriaceae</i>	4 (6.3)	0
<i>Enterobacter aerogenes</i>	3 (4.7)	1	1
<i>Citrobacter koseri</i>	1 (1.6)	0
<i>Klebsiella oxytoca</i>	1 (1.6)	1	1	1	.	.	.
<i>Raoultella Spp.</i>	1 (1.6)	1	1
<i>Serratia marcescens</i>	1 (1.6)	0
Other <i>Citrobacter Spp</i>	1 (1.6)	0
Unknown species	1 (1.6)	0
Total	64	35	29	7	0	0	0

¹not all isolates sent for mechanism testing, some isolates have more than one mechanism

Though January had the highest number of CRE cases by month for the past year, the cases reported to PDPH sharply declined starting in February due to the surge of COVID-19 in Philadelphia

CRE Cases, by Carbapenemase-Producing (CP) Status: April 2019 – March 2020

